期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 215, 期 1, 页码 283-301出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20170600
关键词
-
资金
- National Institutes of Health (NIH) [U01AG046139, P50AG047266, R01AG18454, P01AG020206]
- NIH T32 Basic Microbiology and Infectious Diseases Training Grant [5T32AI007110-34]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007110] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS093362] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [U01AG046139, P30AG028740, P50AG047266, R01AG018454, P01AG020206] Funding Source: NIH RePORTER
Processing of amyloid-beta (A beta) precursor protein (APP) by gamma-secretase produces multiple species of A beta: A beta 40, short A beta peptides (A beta 37-39), and longer A beta peptides (A beta 42-43). gamma-Secretase modulators, a class of Alzheimer's disease therapeutics, reduce production of the pathogenic A beta 42 but increase the relative abundance of short A beta peptides. To evaluate the pathological relevance of these peptides, we expressed A beta 36-40 and A beta 42-43 in Drosophila melanogaster to evaluate inherent toxicity and potential modulatory effects on A beta 42 toxicity. In contrast to A beta 42, the short A beta peptides were not toxic and, when co-expressed with A beta 42, were protective in a dose-dependent fashion. In parallel, we explored the effects of recombinant adeno-associated virus-mediated expression of A beta 38 and A beta 40 in mice. When expressed in nontransgenic mice at levels sufficient to drive A beta 42 deposition, A beta 38 and A beta 40 did not deposit or cause behavioral alterations. These studies indicate that treatments that lower A beta 42 by raising the levels of short A beta peptides could attenuate the toxic effects of A beta 42.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据